China Health Group Valuation

Is 673 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 673 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 673's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 673's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 673?

Key metric: As 673 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 673. This is calculated by dividing 673's market cap by their current revenue.
What is 673's PS Ratio?
PS Ratio	5.7x
Sales	HK$59.93m
Market Cap	HK$339.23m

673 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.7x
Enterprise Value/EBITDA	-10.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 673's PS Ratio compare to its peers?

The above table shows the PS ratio for 673 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	1.1x
718 Tai United Holdings	1.3x	n/a	HK$225.8m
2427 Guanze Medical Information Industry (Holding)	2.8x	n/a	HK$370.5m
6833 Sinco Pharmaceuticals Holdings	0.1x	n/a	HK$370.0m
1110 Kingworld Medicines Group	0.2x	n/a	HK$252.1m
673 China Health Group	5.7x	n/a	HK$339.2m

Price-To-Sales vs Peers: 673 is expensive based on its Price-To-Sales Ratio (5.7x) compared to the peer average (1.1x).

Price to Sales Ratio vs Industry

How does 673's PS Ratio compare vs other companies in the HK Healthcare Industry?

11 Companies	Price / Sales	Estimated Growth	Market Cap
1099 Sinopharm Group	0.1x	5.8%	US$8.04b
9885 YSB	0.2x	n/a	US$505.51m
2289 Charmacy Pharmaceutical	0.2x	n/a	US$128.47m
9955 ClouDr Group	0.2x	23.5%	US$90.50m

11 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 673 is expensive based on its Price-To-Sales Ratio (5.7x) compared to the Hong Kong Healthcare industry average (0.9x).

Price to Sales Ratio vs Fair Ratio

What is 673's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

673 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	5.7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 673's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sinopharm Group

HK$62.6b

Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.

1099

HK$20.05

-0.7%

0.3%

OrbusNeich Medical Group Holdings

HK$3.4b

An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.

6929

HK$4.10

-5.7%

-48.6%

Hygeia Healthcare Holdings

HK$10.2b

Offers oncology healthcare services in the People's Republic of China.

6078

HK$16.40

-6.6%

-66.9%